Aenova Leases Tablet Site to Enter U.S. Market

PAEHL, GermanyAenova is leasing a tablet manufacturing site in Lyon, France, which will allow the company to enter the U.S. market for tablet products and strength its presence in France. The site, owned by SkyePharma, is EMEA and FDA certified, and manufactures complex tablet products for the European and U.S. markets.

In its financial report of 2010, Aenova said it had the goal to expand sales outside of Germany; with this new agreement, the company said it would also like to focus on increasing its analytical development. The site has top trained and motivated employees and has highly modern equipment," said Heiner Hoppmann, CEO of Aenova. For both companies, this partnership is an excellent solution."

The agreement will also allow Aenova to increase utilization of the SkyePharmas facility, and enables SkyePharma to focus on its core business of developing drug delivery solutions for the global pharmaceutical industry, according to Axel Müller, CEO of SkyePharma.

 The newly established Aenova France assumes responsibility, under the lease agreement, for all employees (approximately 90) of the SkyePharma site in Saint Quentin-Fallavier.

Aenova Holding GmbH was formed in 2008 through the merger of two high-profile, mid-sized companies: Dragenopharm Apotheker Püschl GmbH and SWISS CAPS AG. The Aenova Group is a manufacturer and supplier of pharmaceutical and health supplements in modern oral dosage forms such as soft gelatin capsules, hard capsules, tablets, film tablets, sugar-coated tablets and effervescence tablets. The Aenova Group generates annual sales of approx. 250m and has around 1,500 employees across its sites in Germany, Switzerland, Romania and the United States.